$TXTM “With the acquisition of Cannabis Biosciences, Inc. in March 2017, the Company acquired the license to develop cannabis medicines using the patented extraction methods, which research indicates should produce a full-profile, highly-bioavailable extract without the associated psychoactive properties of THC.”